Several clinical trials have assessed the benefits of targeting BCMA for the treatment of MM either with anti-BCMA bispecific T-cell engagers (BiTE) or anti-BCMA antibody-drug conjugates (49, 50). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.